This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Let's collaborate Boehringer Ingelheim

ASCO, Chicago, IL, USA, 1-5 June 2018

Afatinib in combination with pembrolizumab in patients with Stage IIIB/IV squamous cell carcinoma of the lung

Benjamin Levy, Luis Paz-Ares, Jaafar Bennouna, Enriqueta Felip, Delvys Abreu, Dolores Isla, Fabrice Barlesi, Olivier Molinier, Jeannick Madelaine, Clarisse Audigier-Valette, Sang-We Kim, Hye Ryun Kim, Mustafa Ozguroglu, Mustafa Erman, Firas B Badin, Tarek Mekhail, Ronald J. Scheff, Michael J. Chisamore, Behbood Sadrolhefazi, Jonathan W. Riess

Levy et al TiP ASCO 2018 poster

Related Material

Learn more about the science behind this poster in the videos, papers and other materials below.

New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib

Hirsh V. Onco Targets Ther. 2017 May 11;10:2513-2526

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

Soria JC, et al. Lancet Oncol 2015;16(8):897–907

Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy

Felip E, et al. Clinical Lung Cancer, In press

FOR HEALTHCARE PROFESSIONALS ONLY.

 

In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.

Related information

ASCO 2018

Find information on Boehringer Ingelheim's clinical data and activities at ASCO 2018

 

About afatinib

A detailed look at afatinib’s mechanism of action and the ErbB Family of receptors that are targeted by afatinib
Back to top